Hepatitis
Hepatitis 02/02/2010
Engineering a new way to study hepatitis C
Hepatitis C, a virus that can cause liver failure or cancer, infects about 200 million people worldwide. Existing drugs are not always effective, so many patients end up on long liver-transplant waiting lists.
Hepatitis 31/01/2010
Conatus Pharmaceuticals initiates Phase II clinical trial in combination with pegylated interferon and ribavirin for the treatment of hepatitis C virus
Conatus Pharmaceuticals announced the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon and ribavirin in refractory HCV patients.
Hepatitis 31/01/2010
31 percent respond to hep C retreatment after first course fails
Roughly 31 percent of people coinfected with both HIV and hepatitis C virus can be successfully retreated for HCV after a first course of treatment has failed.
Hepatitis 28/01/2010
Achillion announces nomination of ACH-2684 as lead clinical candidate in resistance-focused HCV program
Compound demonstrates excellent potency against HCV and retains activity against resistant variants.
Hepatitis 28/01/2010
Kidney dysfunction more frequent, increases risk of death of patients with HIV and hepatitis C co-infection
Hepatitis C co-infection is associated with an increased risk of kidney disease and death for HIV-positive individuals, US investigators report in the February 1st edition of the Journal of Acquired Immune Deficiency Syndromes.
Hepatitis 28/01/2010
Lab-grown liver cells provide model for hepatitis C infection
Researchers have developed a new method for growing human liver cells outside the body. Scientists can now study hepatitis C virus in the lab over a period of weeks – which may boost efforts to develop a vaccine or broadly effective treatment for the infection.
Hepatitis 28/01/2010
Achillion pharma at a glance
Achillion's product pipeline includes ACH-1625 and ACH-1095 for the treatment of chronic hepatitis C infection; ACH-702 for the treatment of serious, resistant bacterial infections and Elvucitabine for the treatment of HIV.
Hepatitis 27/01/2010
Dynavax hepatitis C drug shows promise in phase 1 trial
Drug SD-101 was safe and showed anti-viral response.
Hepatitis 23/01/2010
Anadys provides progress update on Phase II study of ANA598 in hepatitis C patients
ANA598 dosing completed in the 200 mg bid cohort; Enrollment completed in the 400 mg bid cohort.
Hepatitis 21/01/2010
Tree shrew offers small-animal model of hepatitis C virus infection
This discovery would replace the need for rare and expensive studies using chimpanzees, currently the only validated animal model for HCV.
Hepatitis 21/01/2010
Pharmasset initiates Phase 2a trial with PSI-7977, a chirally pure isomer of PSI-7851
The trial will evaluate various doses of PSI-7977 in combination with Pegasys and Copegus in patients with HCV genotype 1 who have not been treated previously.
Hepatitis 20/01/2010
New treatment eyed for hepatitis C
Class of compounds identified that inhibits viral growth in lab tests.
Hepatitis 19/01/2010
Telaprevir may be viewed more positively by clinicians than boceprevir for hepatitis C virus treatment following their launches in 2011
Uptake of telaprevir and boceprevir will be key drivers of substantial overall market growth through 2013, according to new findings from Decision Resources.
Hepatitis 15/01/2010
Treatment for chronic hepatitis C: A phase II study
The addition of ketoprofen to the conventional combination therapy is associated with better viral kinetics and early activation of the IFNa signaling pathway, thus improving virological response rates.
Hepatitis 14/01/2010
A novel and simple formula to predict treatment success in chronic hepatitis C
The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy.
Hepatitis 13/01/2010
Experimental CCR5 antagonist vicriviroc appears safe and well tolerated in HIV/HCV coinfected patients
Vicriviroc did not affect hepatitis C virus levels, but it also did not lower HIV viral load as intended.
Hepatitis 12/01/2010
Vertex to ask for telaprevir OK later in 2010
Telaprevir is one of several potential hepatitis C treatments in development. If approved, it could face competition from Schering-Plough Corp.'s experimental hepatitis C drug boceprevir.
Hepatitis 12/01/2010
Idenix Pharmaceuticals highlights progress in three HCV programs
Interim analysis of 50 mg cohort demonstrates potent HCV antiviral activity at 14 days for IDX184 in combination with PegIFN/Ribavirin; IDX375 exhibited favorable pharmacokinetic properties in a Phase I healthy volunteer study; Clinical Trial Application filed in December 2009 for IDX320.
Hepatitis 12/01/2010
Achillion announces additional positive Phase 1b data with ACH-1625 to treat hepatitis C
Second dosing cohort achieves 4.25log10 viral load reduction with continued safety and tolerability.
Hepatitis 07/01/2010
OraSure Technologies files additional data with FDA in support of PMA application for OraQuick Rapid HCV Test
The amendment contains additional clinical data requested by the FDA for use of the test in detecting antibodies to the Hepatitis C Virus in venous whole blood samples.
More...
